01 — What is it?
KPV is a C-terminal tripeptide derived from α-MSH. Cell and animal studies report anti-inflammatory effects involving NF-κB and related signaling; human therapeutic evidence is not established.
Database / Research Profiles / KPV
RESEARCH PROFILE
KPV
Lys-Pro-Val • α-MSH-derived tripeptide
Inflammation / barrier biologyPreclinical
EVIDENCE SNAPSHOTPRECLINICAL
Evidence is predominantly cell and animal research. KPV should not be presented as a clinically validated anti-inflammatory treatment.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Inflammation / barrier biology. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: LIMITED / NONEPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
Evidence is predominantly cell and animal research. KPV should not be presented as a clinically validated anti-inflammatory treatment.
04 — Mechanism / biology
KPV is a C-terminal tripeptide derived from α-MSH. Cell and animal studies report anti-inflammatory effects involving NF-κB and related signaling; human therapeutic evidence is not established.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.